Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Furth...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of the American College of Cardiology Ročník 72; číslo 25; s. 3246
Hlavní autori: Ghorbani, Anahita, Bhambhani, Vijeta, Christenson, Robert H, Meijers, Wouter C, de Boer, Rudolf A, Levy, Daniel, Larson, Martin G, Ho, Jennifer E
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 25.12.2018
Predmet:
Aged
Biomarkers - blood
Blood Proteins
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - mortality
Cohort Studies
Female
Galectin 3 - blood
Galectins
Humans
Incidence
Longitudinal Studies
Male
Middle Aged
Mortality - trends
Prospective Studies
mortality
cardiovascular disease
heart failure
biomarker
change in galectin-3
galectin-3
ISSN:1558-3597, 1558-3597
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
AbstractList Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.BACKGROUNDGalectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.OBJECTIVESThe authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3.METHODSA total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3.The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both).RESULTSThe following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both).Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.CONCLUSIONSLongitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
Author Bhambhani, Vijeta
Christenson, Robert H
Levy, Daniel
Larson, Martin G
Ho, Jennifer E
Meijers, Wouter C
Ghorbani, Anahita
de Boer, Rudolf A
Author_xml – sequence: 1
  givenname: Anahita
  surname: Ghorbani
  fullname: Ghorbani, Anahita
  organization: Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, Connecticut
– sequence: 2
  givenname: Vijeta
  surname: Bhambhani
  fullname: Bhambhani, Vijeta
  organization: Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
– sequence: 3
  givenname: Robert H
  surname: Christenson
  fullname: Christenson, Robert H
  organization: Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland
– sequence: 4
  givenname: Wouter C
  surname: Meijers
  fullname: Meijers, Wouter C
  organization: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
– sequence: 5
  givenname: Rudolf A
  surname: de Boer
  fullname: de Boer, Rudolf A
  organization: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
– sequence: 6
  givenname: Daniel
  surname: Levy
  fullname: Levy, Daniel
  organization: National Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, Massachusetts; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
– sequence: 7
  givenname: Martin G
  surname: Larson
  fullname: Larson, Martin G
  organization: Framingham Heart Study, Framingham, Massachusetts; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
– sequence: 8
  givenname: Jennifer E
  surname: Ho
  fullname: Ho, Jennifer E
  email: jho1@mgh.harvard.edu
  organization: Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jho1@mgh.harvard.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30573026$$D View this record in MEDLINE/PubMed
BookMark eNpNj81Kw0AYRQep2B99ARcySzeJ85OZzCwl2FoodKPr8GXypU5JJjWTCL69Qiu4OndxuHCWZBb6gITcc5ZyxvXTMT2Cc6lg3KTMpizXV2TBlTKJVDaf_dtzsozxyBjThtsbMpdM5ZIJvSDrXR8OfpxqH6ClxQeEA1If6AZadKMPiaQQaroNztcYRlrAUPv-C6KbWhjofhpd32G8JdcNtBHvLlyR9_XLW_Ga7PabbfG8S5xWakykNCiNQuUwgzyrjW64sFojk42wmai048BBZxaZaiqpHLC8YpWsFK-MkGJFHs-_p6H_nDCOZeejw7aFgP0US8GVtSbLhP1VHy7qVHVYl6fBdzB8l3_t4gfsMl0W
CitedBy_id crossref_primary_10_1161_JAHA_123_031607
crossref_primary_10_3390_biom13010173
crossref_primary_10_3389_fcvm_2022_818162
crossref_primary_10_3389_fcvm_2021_706490
crossref_primary_10_1155_ijvm_7431078
crossref_primary_10_1016_j_mayocp_2022_10_013
crossref_primary_10_1111_ctr_14592
crossref_primary_10_3390_ijms23105680
crossref_primary_10_1016_j_ijcard_2024_132723
crossref_primary_10_1007_s00380_022_02222_9
crossref_primary_10_3389_fcvm_2021_829151
crossref_primary_10_1056_NEJMra1916393
crossref_primary_10_3390_jcdd8110139
crossref_primary_10_1007_s11906_021_01135_8
crossref_primary_10_1002_smll_202305940
crossref_primary_10_1016_j_cardfail_2025_02_014
crossref_primary_10_1161_JAHA_121_023238
crossref_primary_10_1016_j_jacc_2019_01_045
crossref_primary_10_3390_ijms241713111
crossref_primary_10_1002_ehf2_13174
crossref_primary_10_1371_journal_pone_0298284
crossref_primary_10_1016_j_cca_2020_07_040
crossref_primary_10_1093_eurheartj_ehac128
crossref_primary_10_3390_ijms22062955
crossref_primary_10_1007_s00246_025_03935_0
crossref_primary_10_1161_JAHA_119_015405
crossref_primary_10_1016_j_diabres_2020_108082
crossref_primary_10_1016_j_xkme_2025_101089
crossref_primary_10_1002_ehf2_12612
crossref_primary_10_1111_bph_14674
crossref_primary_10_1055_s_0040_1721144
crossref_primary_10_1186_s12889_024_18811_4
crossref_primary_10_1016_j_jacc_2018_09_077
crossref_primary_10_1016_j_clnu_2025_03_001
crossref_primary_10_1002_ejhf_1771
crossref_primary_10_1158_0008_5472_CAN_20_2799
crossref_primary_10_1161_CIRCRESAHA_121_319916
crossref_primary_10_1016_j_jaccao_2023_03_015
crossref_primary_10_2217_bmm_2018_0488
crossref_primary_10_3390_jcm14103345
crossref_primary_10_1007_s11255_019_02123_3
crossref_primary_10_3390_cimb47050332
crossref_primary_10_3389_fcvm_2023_1175174
crossref_primary_10_1016_j_numecd_2022_03_001
crossref_primary_10_1155_2019_9529053
crossref_primary_10_1007_s40256_019_00387_9
crossref_primary_10_1016_j_jacc_2019_02_016
crossref_primary_10_1093_eurheartj_ehac034
crossref_primary_10_1002_ehf2_13118
crossref_primary_10_1253_circj_CJ_25_0002
crossref_primary_10_3390_ijms21239232
crossref_primary_10_1007_s40200_022_01044_w
crossref_primary_10_1007_s11897_024_00686_6
crossref_primary_10_1016_j_scib_2024_03_042
crossref_primary_10_3390_biom10030389
crossref_primary_10_3389_fphys_2023_1090724
ContentType Journal Article
Copyright Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jacc.2018.09.076
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1558-3597
ExternalDocumentID 30573026
Genre Journal Article
Observational Study
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL134893
– fundername: NHLBI NIH HHS
  grantid: HHSN268201500001I
– fundername: NHLBI NIH HHS
  grantid: K23 HL116780
– fundername: NHLBI NIH HHS
  grantid: N01 HC025195
– fundername: NHLBI NIH HHS
  grantid: R01 HL140224
– fundername: NHLBI NIH HHS
  grantid: HHSN268201500001C
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
18M
1B1
1P~
1~.
1~5
2WC
4.4
457
4G.
53G
5GY
5RE
5VS
6PF
7-5
71M
8P~
AABNK
AABVL
AAEDT
AAEDW
AAIKJ
AAKUH
AALRI
AAOAW
AAQFI
AAQQT
AAXUO
ABBQC
ABFNM
ABFRF
ABLJU
ABMAC
ABMZM
ABOCM
ACGFO
ACGFS
ACIUM
ACJTP
ACPRK
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFCTW
AFETI
AFPUW
AFRAH
AFRHN
AFTJW
AGCQF
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BLXMC
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FNPLU
G-Q
GBLVA
GX1
H13
HVGLF
IHE
IXB
J1W
K-O
KQ8
L7B
MO0
N9A
NPM
O-L
O9-
OA.
OAUVE
OK1
OL~
OZT
P-8
P-9
P2P
PC.
PQQKQ
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SSZ
TR2
UNMZH
UV1
W8F
WH7
WOQ
WOW
YYM
YZZ
Z5R
7X8
EFLBG
~HD
ID FETCH-LOGICAL-c655t-338e385e5ce4a74d86f12966e03f2942b6c1a1a649e05fb35ca07b0b3b51b8232
IEDL.DBID 7X8
ISICitedReferencesCount 62
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000453380000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1558-3597
IngestDate Sun Nov 09 14:04:27 EST 2025
Mon Jul 21 05:35:37 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 25
Keywords mortality
cardiovascular disease
heart failure
biomarker
change in galectin-3
galectin-3
Language English
License Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c655t-338e385e5ce4a74d86f12966e03f2942b6c1a1a649e05fb35ca07b0b3b51b8232
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.clinicalkey.com/#!/content/1-s2.0-S073510971838906X
PMID 30573026
PQID 2159984429
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2159984429
pubmed_primary_30573026
PublicationCentury 2000
PublicationDate 2018-12-25
PublicationDateYYYYMMDD 2018-12-25
PublicationDate_xml – month: 12
  year: 2018
  text: 2018-12-25
  day: 25
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of the American College of Cardiology
PublicationTitleAlternate J Am Coll Cardiol
PublicationYear 2018
References 30573027 - J Am Coll Cardiol. 2018 Dec 25;72(25):3255-3258. doi: 10.1016/j.jacc.2018.09.077.
30975312 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875-1876. doi: 10.1016/j.jacc.2019.02.016.
30975311 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875. doi: 10.1016/j.jacc.2019.01.045.
References_xml – reference: 30975311 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875. doi: 10.1016/j.jacc.2019.01.045.
– reference: 30573027 - J Am Coll Cardiol. 2018 Dec 25;72(25):3255-3258. doi: 10.1016/j.jacc.2018.09.077.
– reference: 30975312 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875-1876. doi: 10.1016/j.jacc.2019.02.016.
SSID ssj0006819
Score 2.5147867
Snippet Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 3246
SubjectTerms Aged
Biomarkers - blood
Blood Proteins
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - mortality
Cohort Studies
Female
Galectin 3 - blood
Galectins
Humans
Incidence
Longitudinal Studies
Male
Middle Aged
Mortality - trends
Prospective Studies
Title Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
URI https://www.ncbi.nlm.nih.gov/pubmed/30573026
https://www.proquest.com/docview/2159984429
Volume 72
WOSCitedRecordID wos000453380000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGCF4Hk8yak0ixemhrDyq9ldkC9ZBUk_r7fZOkFA-C4CWXITC8efP2-T6Ebhw1IVGWJLEaEpTMUmKMZsTqTAbAN6VqHrK3gRyN1GSSjtuCW9mOVS5tYm2oXWFDjfwWXBNkBgzM5938gwTWqNBdbSk01lGHQigTRrrkZIUWLlRN7AEuUxEKkXP7aKaZ73rXNkAYxqrGOZXi9xCzdjX93f9ucg_ttEEmvm-0Yh-t-fwAbQ3bNvoh6g-KQFO0cIESCzcPDPAsx486FPFnOaFY5w6D7QiUoxXu_Rhaxc-LCrbjyyP02n946T2RllCBWMF5RSAd9VRxz61nWjKnRAbuXggf0SxJWWKEjXWsBUt9xDNDudWRNJGhhsdGQex1jDbyIvenCMMqi5x2sRUpS53WacoclVo7GSWOuS66XkpoCgobuhA698WinK5k1EUnjZin8wZZY0oDPCNkhWd_-PscbYfTC6MlCb9AnQyuq79Em_armpWfV7UmwHc0Hn4DGlK80g
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+Change+in+Galectin-3+and+Incident+Cardiovascular+Outcomes&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Ghorbani%2C+Anahita&rft.au=Bhambhani%2C+Vijeta&rft.au=Christenson%2C+Robert+H&rft.au=Meijers%2C+Wouter+C&rft.date=2018-12-25&rft.eissn=1558-3597&rft.volume=72&rft.issue=25&rft.spage=3246&rft_id=info:doi/10.1016%2Fj.jacc.2018.09.076&rft_id=info%3Apmid%2F30573026&rft_id=info%3Apmid%2F30573026&rft.externalDocID=30573026
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon